TheStreet's Jim Cramer discussed several battered biotech stocks Friday while answering viewer questions from social media with TheStreet's Rhonda Schaffler.
A viewer asked about Regeneron Pharmaceuticals(REGN) - Get Report , particularly that there has been some insider buying recently and the stock is close to a 52-week low. Cramer responded, "Biotech stocks have been under such pressure. I'm not going to say don't buy Regeneron. I like it."
Cramer noted how Celgene(CELG) - Get ReportBiogen(BIIB) - Get Report and Amgen(AMGN) - Get Report have all been slammed. Biogen is among the holdings of Action Alerts PLUS, the charitable trust portfolio managed by Cramer.
Cramer was asked about Oracle(ORCL) - Get Report . "I think Oracle is OK, but I like Salesforce.com(CRM) - Get Report . Salesforce has been winning business and you know what, I'm just feeling very confident about that (company).
A viewer wanted to know if Nestle (NSRGY) is a good long-term hold. "Not if the dollar has peaked, no," said Cramer.
Cramer does like Coca-Cola(KO) - Get Report , which he believes will move much higher. He also likes Pepsico(PEP) - Get Report , which is another holding of Action Alerts PLUS. "I like the snack business," said Cramer. "I like the combination of the two."
At the time of publication, Cramer's Action Alerts PLUS had positions in stocks BIIB and PEP.